Real-World Outcomes of Idecabtagene Vicleucel in relapsed/refractory Multiple Myeloma: Comparative Analysis of Genetically and Clinically Defined High-Risk Versus Standard-Risk Patients from the CIBMTR Registry

Key Points

• Idecabtagene vicleucel improved outcomes in relapsed/refractory multiple myeloma, particularly in high-risk patients.
• Among high-risk patients, there was a notable reduction in disease progression, enhancing overall survival rates.
• Observational analysis retrieved data from the CIBMTR registry on genetically and clinically defined risk categories.
• Findings support the need for tailored treatments in multiple myeloma, emphasizing risks associated with patient classifications.